CN103328427A - 增强受到危害的组织的氧合的方法 - Google Patents

增强受到危害的组织的氧合的方法 Download PDF

Info

Publication number
CN103328427A
CN103328427A CN2011800648610A CN201180064861A CN103328427A CN 103328427 A CN103328427 A CN 103328427A CN 2011800648610 A CN2011800648610 A CN 2011800648610A CN 201180064861 A CN201180064861 A CN 201180064861A CN 103328427 A CN103328427 A CN 103328427A
Authority
CN
China
Prior art keywords
molecular weight
patient
blood
polyoxyethylene
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800648610A
Other languages
English (en)
Chinese (zh)
Inventor
M·埃马努埃莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savara Inc
Original Assignee
Adventrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adventrx Pharmaceuticals Inc filed Critical Adventrx Pharmaceuticals Inc
Publication of CN103328427A publication Critical patent/CN103328427A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800648610A 2010-11-15 2011-11-15 增强受到危害的组织的氧合的方法 Pending CN103328427A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41351910P 2010-11-15 2010-11-15
US61/413,519 2010-11-15
PCT/US2011/060747 WO2012068079A1 (en) 2010-11-15 2011-11-15 Methods for enhancing oxygenation of jeopardized tissue

Publications (1)

Publication Number Publication Date
CN103328427A true CN103328427A (zh) 2013-09-25

Family

ID=46084364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800648610A Pending CN103328427A (zh) 2010-11-15 2011-11-15 增强受到危害的组织的氧合的方法

Country Status (17)

Country Link
US (2) US20130177524A1 (enExample)
EP (1) EP2640684A4 (enExample)
JP (2) JP5823530B2 (enExample)
KR (2) KR20150124457A (enExample)
CN (1) CN103328427A (enExample)
AU (1) AU2011329088B2 (enExample)
BR (1) BR112013011858A2 (enExample)
CA (1) CA2817542A1 (enExample)
CL (1) CL2013001382A1 (enExample)
EA (1) EA201390720A1 (enExample)
IL (1) IL226285A0 (enExample)
MX (1) MX2013005457A (enExample)
NZ (1) NZ610441A (enExample)
PE (1) PE20140134A1 (enExample)
SG (1) SG190695A1 (enExample)
WO (1) WO2012068079A1 (enExample)
ZA (1) ZA201303416B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328427A (zh) * 2010-11-15 2013-09-25 马斯特治疗公司 增强受到危害的组织的氧合的方法
GB201207543D0 (en) * 2012-05-01 2012-06-13 Haemair Ltd Treatment of transfusion blood
CA2927361A1 (en) * 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9403941B2 (en) 2014-07-07 2016-08-02 Mast Therapeutics, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3873441A4 (en) 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
EP4401554A4 (en) * 2021-08-18 2025-10-15 Omniox Inc H-NOX PROTEINS FOR ORGAN PRESERVATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069741A (zh) * 1991-03-19 1993-03-10 西特克斯公司 具有改进的生物活性的聚氧丙烯/聚氧乙烯共聚物
WO2009023177A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
EP1804813A4 (en) * 2004-09-27 2011-09-07 Vical Inc FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN103328427A (zh) * 2010-11-15 2013-09-25 马斯特治疗公司 增强受到危害的组织的氧合的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1069741A (zh) * 1991-03-19 1993-03-10 西特克斯公司 具有改进的生物活性的聚氧丙烯/聚氧乙烯共聚物
WO2009023177A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALAN C.HYMES,ET AL: "THE INFLUENCE OF AN INDUSTRIAL SURFACTANT PLURONIC F-68, IN THE TREATMENT OF HEMORRHAGIC SHOCK", 《JOURNAL OF SURGICAL RESEARCH》, vol. 11, no. 4, 30 April 1971 (1971-04-30), pages 191 - 197 *
DAVID C. MAYER, ET AL.: "Effects of Poloxamer 188 in a rabbit model of hemorrhagic shock", 《 ANNALS OF CLINICAL AND LABORATORY SCIENCE》, vol. 24, no. 4, 31 December 1994 (1994-12-31), pages 302 - 311 *
EUN JUNG BAEK，ET AL: "Stroma-free mass production of clinical-grade red blood cells (RBCs) by using poloxamer 188 as an RBC survival enhancer", 《TRANSFUSION》, vol. 49, 30 November 2009 (2009-11-30), pages 2285 - 2295 *
FREDERICK L.GROVER,ET AL: "The Effect of Pluronic F-68 on Circulatory Dynamics and Renal and Carotid Artery Flow during Hemorrhagic Shock", 《JOURNAL OF SURGICAL RESEARCH》, vol. 17, no. 1, 31 July 1974 (1974-07-31), pages 30 - 35 *

Also Published As

Publication number Publication date
KR20150124457A (ko) 2015-11-05
BR112013011858A2 (pt) 2017-03-21
CA2817542A1 (en) 2012-05-24
CL2013001382A1 (es) 2013-12-20
JP2014506234A (ja) 2014-03-13
PE20140134A1 (es) 2014-02-14
SG190695A1 (en) 2013-07-31
AU2011329088A1 (en) 2013-06-27
EP2640684A1 (en) 2013-09-25
JP5823530B2 (ja) 2015-11-25
IL226285A0 (en) 2013-07-31
AU2011329088B2 (en) 2016-02-25
EA201390720A1 (ru) 2013-10-30
EP2640684A4 (en) 2014-04-30
WO2012068079A1 (en) 2012-05-24
ZA201303416B (en) 2017-03-29
US20130177524A1 (en) 2013-07-11
US20150093368A1 (en) 2015-04-02
NZ610441A (en) 2016-02-26
KR20130097795A (ko) 2013-09-03
JP2016041714A (ja) 2016-03-31
MX2013005457A (es) 2013-10-17

Similar Documents

Publication Publication Date Title
AU2011329088B2 (en) Methods for enhancing oxygenation of jeopardized tissue
Rawal et al. Anemia in intensive care: a review of current concepts
JP2014506234A5 (enExample)
Houry et al. Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: a randomized controlled trial
Carson et al. Anemia and red blood cell transfusion
BRPI0621528A2 (pt) composição farmacêutica contendo lactato e cálcio, e usos da mesma
US20220040195A1 (en) Use of vanadium compounds for maintaining normaglycemia in a mammal
Arnal et al. Pediatric septic shock: Why has mortality decreased?—The utility of goal-directed therapy
CA2085475A1 (en) Hyperosmotic solutions for isonatremic resuscitation
Prough Crystalloids versus colloids in the perioperative period
Riaz et al. Controlled Blood Pressure Rise Through Limited Fluid Resuscitation in Treating Multiple Injuries in Permutation with Shock and its Impact on Post-Resuscitation Hemoglobin Level
Yu et al. SMALL-VOLUME RESUSCITATION FROM TRAUMATIC SHOCK WITH GEKOTON
Li et al. Perioperative fluid therapy: A general overview
Picozzi Concezione Tommasino* MD
Raisis et al. Fluid therapy
Ayhan et al. The effects of non-leukoreduced red blood cell transfusions on microcirculation in mixed surgical patients.
NZ572358A (en) Lactate and calcium containing pharmaceutical composition and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130925